Decibel Therapeutics has hired Steven Holtzman, a former Biogen executive, as its president and chief executive officer. Holtzman has had a long career in executive roles, including as CEO and board director at Infinity Pharmaceuticals and the chief business officer of Millennium Pharmaceuticals. Holtzman most recently came from the role of executive vice president for business operations at Biogen. Cambridge, MA-based Decibel launched in October 2015 with a $52 million Series A from Third Rock Ventures and SR One.
Author: David Holley
David is the national correspondent at Xconomy. He has spent most of his career covering business of every kind, from breweries in Oregon to investment banks in New York. A native of the Pacific Northwest, David started his career reporting at weekly and daily newspapers, covering murder trials, city council meetings, the expanding startup tech industry in the region, and everything between. He left the West Coast to pursue business journalism in New York, first writing about biotech and then private equity at The Deal. After a stint at Bloomberg News writing about high-yield bonds and leveraged loans, David relocated from New York to Austin, TX.
He graduated from Portland State University.
View all posts by David Holley
